Oxford BioDynamics PLC has announced the successful passing of both resolutions proposed at its General Meeting. The company, focused on developing precision medicine tests, will see the admission of new Ordinary Shares to trading on AIM. The VCT/EIS Admission is expected to take place on April 5, 2024, and General Admission on April 8, 2024. Following these admissions, the company's issued ordinary share capital and total voting rights will consist of 220,537,869 and 311,855,650 Ordinary Shares, respectively.
The company also disclosed the details of the New Ordinary Shares subscribed for pursuant to the Placing, the Subscriptions, and the PrimaryBid Offer by the Directors and PDMRs participating in the Fundraising. Additionally, Baden Hill, a related party of the company, will receive commission of £167,135 in relation to their role as joint broker on the Fundraising.
Furthermore, Director/PDMR Dealings were disclosed, including the purchase of Ordinary Shares by Matthew Wakefield and Dr. Jon Burrows. Wakefield purchased 277,777 shares at a price of £0.09, while Burrows purchased 388,888 shares at the same price. These transactions took place off-market on April 3, 2024.
The company's Chairman, Matthew Wakefield, and CEO, Dr. Jon Burrows, were among the Directors and PDMRs who participated in the Fundraising, with Wakefield's beneficial shareholding reaching 1,300,504 shares and Burrows' reaching 1,088,888 shares following the Fundraising.
These announcements provide insight into the company's recent activities, including the successful General Meeting, the admission of new Ordinary Shares, and the details of Director/PDMR dealings and their participation in the Fundraising.